<DOC>
	<DOCNO>NCT01200160</DOCNO>
	<brief_summary>Post-Marketing Observational study Niaspan® tablet accordance country regulation . This study conduct prospective , single-arm , multi-center format . As study observational nature , follow-up subject 's prescriptive nature accord judgment physician ( investigator course treatment patient ) , within period observation 12 month . This include enrollment period 6 month subject observe approximately 6 month . Examinations , diagnostic measure , finding observation perform per usual medical practice observation period record Case Report Forms ( CRFs ) investigator site staff accord protocol .</brief_summary>
	<brief_title>Study Effectiveness Safety Niaspan ® Treatment Lipid Abnormalities Latin America</brief_title>
	<detailed_description>This Post-Marketing Observational study ( PMOS ) Niaspan® tablet accordance country regulation . This study conduct prospective , single-arm , multi-center format . As study observational nature , follow-up subject 's prescriptive nature accord judgment physician ( investigator course treatment patient ) , within period 12 month . This include enrollment period 6 month treatment duration subject observe approximately 6 month . Examinations , diagnostic measure , finding observation perform per usual medical practice observation period record CRFs investigator site staff accord protocol . Prior enrollment study , subject require give write informed consent participate study . Written informed consent include statement authorize use and/or disclosure personal and/or health data . The subject assure patient confidentiality maintain time accord local regulation , data might identify patient collect For patient 's consent participate PMOS study meeting inclusion none exclusion criterion , initial visit baseline well subsequent visit appropriate , demographic , medical history , physical examination , vital sign , flushing/adverse event assessment , concomitant medication information , Niaspan dose change/compliance , lab test document per standard medical practice country , although protocolized manner . If Niaspan® treatment discontinue , subject follow another 1 month adverse event .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Inclusion Criteria Male female subject &gt; 18 yearsold Subjects primary hyperlipidemia mixed dyslipidemia elevate level total cholesterol , , LDLC ( lowdensity lipoproteincholesterol ) , triglycerides and/or decrease level HDLC ( highdensity lipoproteincholesterol ) ( &lt; 40 mg/dL ) demonstrate inadequate response lipidrestricted diet nonpharmacologic measure alone exercise Subject demonstrate persistent dyslipidemic value and/or inadequate response intolerance pharmacologic therapy statin , fibrates , resin , etc . Female subject reproductive potential must use approved contraceptive method ( intrauterine device ( IUD ) , birth control pill barrier device ) 3 month discontinuation study treatment . Exclusion Criteria Subject treat investigational product last 30 day day screen visit Subject exhibit sign acute illness clinically relevant finding prestudy examination Subject know hypersensitivity niacin component Niaspan® Subject significant unexplained hepatic and/or renal dysfunction Subject active peptic ulcer disease Subject exhibit active arterial bleeding Subject pregnant lactate The mental condition subject render him/her unable understand nature , scope , possible consequence study Subject unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Low-Density Lipoprotein Cholesterol</keyword>
	<keyword>Hypertriglyceridemia</keyword>
	<keyword>Latin America</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Sedentary Lifestyle</keyword>
	<keyword>High-Density Lipoprotein Cholesterol</keyword>
</DOC>